What's in Bioverativ, a Sanofi company's pipeline?

Bioverativ, a Sanofi company has 6 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 4 in Phase 1.

Which companies overlap with Bioverativ, a Sanofi company's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bioverativ-a-sanofi-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Bioverativ, a Sanofi company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioverativ, a Sanofi company pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
BIVV009	BIVV009	phase 3	TFPI inhibitor monoclonal antibody	Tissue Factor Pathway Inhibitor (TFPI)	Hematology
sutimlimab (BIVV009)	sutimlimab (BIVV009)	phase 3

Therapeutic area mix

Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Bioverativ, a Sanofi company:

Cite this brief

Drug Landscape (2026). Bioverativ, a Sanofi company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioverativ-a-sanofi-company. Accessed 2026-05-17.